Gelteq Limited Ordinary Shares
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nathan Jacob Givoni
- Full Time Employees
- 18
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 641 Glen Huntly Road Caulfield VIC Australia 3162
- IPO Date
- Oct 29, 2024
- CIK
- 0001920092
- Website
- gelteq.com
- Similar Companies
- Business
- Gelteq Limited Gelteq Limited (GELS) is an Australia-based clinical-stage biotechnology company that develops and commercializes white-label gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care products, sports supplements, and over-the-counter medications; its patented edible gel platform addresses dysphagia-related swallowing difficulties, taste masking, dosage accuracy, and bioavailability limitations in traditional oral formats while enabling integration of water-soluble, lipid-soluble, and combination compounds for human and animal applications. The company offers end-to-end services encompassing R&D under GLP standards, formulation development, non-clinical testing, Phase I-III clinical batch production, and GMP-scale manufacturing; it provides pre-formulated, market-ready proprietary gels for white-labeling alongside custom conversions of existing products into gel formats targeting pharmaceutical, nutraceutical, and veterinary markets. Founded in 2017 and headquartered in Caulfield South, Victoria, Australia, with U.S. operations supported through investor relations in Texas, Gelteq Limited conducts geographic activities primarily in Australia, the United States, and Asia-Pacific regions, serving partners in healthcare, nutrition, and animal health sectors. Recent developments include a July 2025 memorandum of understanding with IDT Australia Limited IDT Australia Limited to establish dedicated manufacturing facilities for scaling gel production across pharmaceutical, nutraceutical, and animal health markets; a June 2025 exclusive North American fulfillment and logistics partnership with Healthy Extracts Inc. to manage storage, shipping, and inventory; and November 2025 announcement of positive preclinical data demonstrating enhanced bioavailability from its proprietary gel delivery system.
Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs
Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications
Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications
Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion
Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway
Healthy Extracts Q1 2026 Net Revenue Up 73% to Record $1.6 Million, Driving Positive EBITDA
Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth
Healthy Extracts Reports 2025 Net Revenue Up 45% to Record $4.5 Million
Healthy Extracts Reports Preliminary 2025 Results, Net Revenue Expected Up 45% to Record $4.5 Million
Gelteq (NASDAQ:GELS) Stock Price Down 3.2% – Here’s What Happened
Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership
What's Driving Gelteq Ltd.'s (GELS) Over 69% After-Hours Surge?
Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform
Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program
Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq's Nutritional Product Expansion into China
Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform
Gelteq to Present at Investor Summit Virtual on December 9, 2025
Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform
Healthy Extracts Reports Record Q3 2025, with Revenue up 23%
Nutraceutical Technology Leader, Healthy Extracts, Invited to Present at the Trickle Research Microcap Conference on November 13, 2025